IN8bio, Inc. (INAB) 10-Year Financial Performance & Capital Metrics

INAB • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutIN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Show more

Revenue $0
EBITDA -$28M +0.2%
Net Income -$30M -1.4%
EPS (Diluted) -0.57 +43.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -154.44% -22.7%
ROIC -269.58% -12.4%
Debt/Equity 0.35 +77.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 79.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM35.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-198.87%

ROCE

10Y Avg-96.58%

5Y Avg-93.44%

3Y Avg-108.66%

Latest-131.83%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	96K	96K	0	0	0	2.5M	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	-96K	-96K	0	0	0	-2.5M	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	0%	1%	-	-	-	1%
Operating Expenses+	2M	5.07M	8.56M	14.65M	28.52M	27.84M	30.44M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	1.42M	2.71M	3.18M	7.31M	14.46M	13.51M	12.64M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	581K	2.36M	5.38M	7.35M	14.06M	16.83M	16.96M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	-63K	0	0	0	0	-2.5M	838K
Operating Income+	-2M	-5.13M	-8.56M	-14.65M	-28.52M	-30.34M	-30.44M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-1.56%	-0.67%	-0.71%	-0.95%	-0.06%	-0%
EBITDA+	-1.91M	-5.04M	-8.47M	-13.87M	-27.42M	-27.84M	-27.78M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-1.64%	-0.68%	-0.64%	-0.98%	-0.02%	0%
D&A (Non-Cash Add-back)	96K	96K	88K	788K	1.1M	2.5M	2.65M
EBIT	-2.07M	-5.13M	-8.56M	-14.65M	-28.52M	-30.01M	-29.6M
Net Interest Income+	0	0	0	0	0	0	230K
Interest Income	0	0	0	0	0	0	230K
Interest Expense	14K	0	0	0	0	0	0
Other Income/Expense	-77K	0	0	0	0	330K	0
Pretax Income+	-2.08M	-5.13M	-8.56M	-14.65M	-28.52M	-30.01M	-30.44M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.08M	-5.13M	-8.56M	-14.65M	-28.52M	-30.01M	-30.44M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-1.47%	-0.67%	-0.71%	-0.95%	-0.05%	-0.01%
Net Income (Continuing)	-2.08M	-5.13M	-8.56M	-14.65M	-28.52M	-30.01M	-30.44M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.11	-0.27	-0.53	-0.78	-1.36	-1.00	-0.57
EPS Growth %	-	-1.45%	-0.96%	-0.47%	-0.74%	0.26%	0.43%
EPS (Basic)	-0.11	-0.27	-0.53	-0.78	-1.36	-1.00	-0.57
Diluted Shares Outstanding	19.35M	19.35M	19.35M	18.78M	20.97M	29.86M	53.55M
Basic Shares Outstanding	19.35M	19.35M	19.35M	18.78M	20.97M	29.86M	53.55M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.07M	763K	18.14M	38.98M	22.23M	24.63M	12.58M
Cash & Short-Term Investments	4.99M	610K	17.99M	37.02M	18.18M	21.28M	11.12M
Cash Only	4.99M	610K	17.99M	37.02M	18.18M	21.28M	11.12M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	30K	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	15K	0	0	0	0	0	0
Days Inventory Outstanding	57.03	-	-	-	-	-	-
Other Current Assets	37K	0	0	52K	232K	270K	298K
Total Non-Current Assets+	823K	367K	2.77M	3.24M	10.8M	9.08M	8.37M
Property, Plant & Equipment	795K	274K	186K	2.83M	10.3M	8.57M	7.83M
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	126K	0	0
Long-Term Investments	0	0	0	0	252K	256K	266K
Other Non-Current Assets	28K	93K	2.58M	409K	381K	255K	275K
Total Assets+	5.89M	1.13M	20.91M	42.22M	33.04M	33.71M	20.94M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	-0.81%	17.5%	1.02%	-0.22%	0.02%	-0.38%
Total Current Liabilities+	419K	647K	2.57M	2.26M	5.82M	5.39M	3.08M
Accounts Payable	419K	560K	620K	395K	2.09M	924K	389K
Days Payables Outstanding	1.59K	2.13K	-	-	-	134.85	-
Short-Term Debt	0	0	174K	0	0	0	1.65M
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	0	0	876K	926K	1.46M	1.67M	1.05M
Current Ratio	12.11x	1.18x	7.05x	17.28x	3.82x	4.57x	4.08x
Quick Ratio	12.07x	1.18x	7.05x	17.28x	3.82x	4.57x	4.08x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	829K	829K	17K	1.78M	4.49M	3.38M	3.38M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	1.78M	4.49M	3.38M	3.38M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	829K	829K	17K	0	0	0	0
Total Liabilities	1.25M	1.48M	2.59M	4.04M	10.31M	8.77M	6.47M
Total Debt+	0	0	174K	2.41M	5.87M	4.89M	5.03M
Net Debt	-4.99M	-610K	-17.82M	-34.61M	-12.31M	-16.39M	-6.09M
Debt / Equity	-	-	0.01x	0.06x	0.26x	0.20x	0.35x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-143.14x	-	-	-	-	-	-
Total Equity+	4.65M	-346K	18.32M	38.18M	22.73M	24.94M	14.48M
Equity Growth %	-	-1.07%	53.95%	1.08%	-0.4%	0.1%	-0.42%
Book Value per Share	0.24	-0.02	0.95	2.03	1.08	0.83	0.27
Total Shareholders' Equity	4.65M	-346K	18.32M	38.18M	22.73M	24.94M	14.48M
Common Stock	1K	1K	1K	2K	3K	4K	7K
Retained Earnings	-4.35M	-9.48M	-18.04M	-32.69M	-61.21M	-91.22M	-121.66M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.77M	-4.8M	-7.13M	-13.51M	-24.12M	-23.34M	-24.15M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.73%	-0.49%	-0.89%	-0.79%	0.03%	-0.03%
Net Income	-2.08M	-5.13M	-8.56M	-14.65M	-28.52M	-30.01M	-30.44M
Depreciation & Amortization	96K	96K	88K	788K	1.1M	2.5M	2.65M
Stock-Based Compensation	31K	0	357K	2.19M	3.47M	0	5M
Deferred Taxes	0	0	0	-541K	-4.16M	0	0
Other Non-Cash Items	70K	144K	368K	541K	4.16M	4.37M	45K
Working Capital Changes	-885K	93K	611K	-1.84M	-170K	-204K	-1.41M
Change in Receivables	-30K	30K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	-152K	141K	-160K	-319K	1.51M	-981K	-535K
Cash from Investing+	-757K	356K	0	-309K	-3.71M	-600K	-187K
Capital Expenditures	-757K	-330K	0	-309K	-3.71M	-600K	-104K
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	-83K
Cash from Financing+	8.5M	65K	24.52M	32.95M	8.99M	27.04M	14.18M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	7.24M	0	-1.33M	-2.66M	61K	0	5.04M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-3.53M	-5.13M	-7.13M	-13.82M	-27.83M	-23.94M	-24.25M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-0.46%	-0.39%	-0.94%	-1.01%	0.14%	-0.01%
FCF per Share	-0.18	-0.27	-0.37	-0.74	-1.33	-0.80	-0.45
FCF Conversion (FCF/Net Income)	1.33x	0.94x	0.83x	0.92x	0.85x	0.78x	0.79x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-44.78%	-238.74%	-95.21%	-51.87%	-93.64%	-125.9%	-154.44%
Return on Invested Capital (ROIC)	-	-	-	-539.64%	-305.67%	-239.86%	-269.58%
Debt / Equity	-	-	0.01x	0.06x	0.26x	0.20x	0.35x
Interest Coverage	-143.14x	-	-	-	-	-	-
FCF Conversion	1.33x	0.94x	0.83x	0.92x	0.85x	0.78x	0.79x

Frequently Asked Questions

Growth & Financials

IN8bio, Inc. (INAB) grew revenue by 0.0% over the past year. Growth has been modest.

IN8bio, Inc. (INAB) reported a net loss of $20.7M for fiscal year 2024.

Dividend & Returns

IN8bio, Inc. (INAB) has a return on equity (ROE) of -154.4%. Negative ROE indicates the company is unprofitable.

IN8bio, Inc. (INAB) had negative free cash flow of $14.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener